Comparative post-therapeutic dosimetry between 2D planar-based and hybrid-based methods for personalized Lu-177 treatment.

Purpose: This study aims to compare the calculated absorbed dose in target organs and tumors obtained using the different imaging protocols and the calculation methodologies implemented by HERMES HybridViewer dosimetry software for Lu-PSMA I&T and Lu-DOTATATE therapy.

Methods: Multiple time-point whole-body planar images and one SPECT/CT image were acquired from 18 patients including Lu-PSMA I&T (13 patients) and Lu-DOTATATE treatment (5 patients) after administration of 3.80-8.

Combined clinical variable and radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low-risk papillary thyroid carcinoma patients.

To explore the feasibility of combined radiomics of post-treatment I-131 total body scan (TBS) and clinical parameter to predict successful ablation in low-risk papillary thyroid carcinoma (PTC) patients. Data of low-risk PTC patients who underwent total/near total thyroidectomy and I-131 ablation 30 mCi between April 2015 and July 2021 were retrospectively reviewed. The clinical factors studied included age, sex, and pre-ablative serum thyroglobulin (Tg).

Delayed Imaging Improves Lesion Detectability in [Tc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer.

Our objective was to compare the ability to detect histopathologically confirmed lymph node metastases by early and delayed [Tc]Tc-PSMA-I&S SPECT/CT in early biochemically recurrent prostate cancer. We retrospectively analyzed 222 patients selected for radioguided surgery using [Tc]Tc-PSMA-I&S SPECT/CT at different time points after injection (≤4 h and >15 h). In total, 386 prostate-specific membrane antigen (PSMA) PET predetermined lesions were analyzed on SPECT/CT using a 4-point scale, and the results were compared between early and late imaging groups, with uni- and multivariate analyses performed including prostate-specific antigen, injected [Tc]Tc-PSMA-I&S activity, Gleason grade group, initial TNM stage, and, stratified by size, PSMA PET/CT-positive lymph nodes.

Dual-Tracer Parathyroid Imaging Using Joint SPECT Reconstruction.

Purpose: We assessed the lesion detection performance of the dual-tracer parathyroid SPECT imaging using the joint reconstruction method.

Materials And Methods: Thirty-six noise realizations were created from SPECT projections collected from an in-house neck phantom to emulate Tc-pertechnetate/Tc-sestamibi parathyroid SPECT datasets. Difference images representing parathyroid lesions were reconstructed using the subtraction and the joint methods whose corresponding optimal iteration was defined as the iteration which maximized the channelized Hotelling observer signal-to-noise ratio (CHO-SNR).

Prognostic Role of Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy.

This study was performed to assess the prognostic utility of conventional biochemical and imaging response criteria and Ga-PSMA11 PET-adapted or -specific systems regarding overall survival (OS) in men with metastatic hormone-sensitive and castration-resistant prostate cancer (PC) treated with taxane-based chemotherapy. A total of 103 patients (metastatic hormone-sensitive PC, = 57; castration-resistant PC, = 46) underwent taxane-based chemotherapy. All patients had a minimum of 2 prostate-specific membrane antigen (PSMA) PET scans (at baseline and up to 3 mo after treatment).

Comparison of the Diagnostic Performance of Myocardial Perfusion Scintigraphy with and Without Attenuation Correction.

Objectives: Myocardial perfusion scintigraphy (MPS) is an important diagnostic test for detecting of coronary artery stenosis (CAS); however, tissue attenuation can lead to a difference in accuracy. We evaluated the diagnostic accuracy of attenuation-corrected (AC) and non-attenuation-corrected (NC) MPS for the detection of CAS.

Methods: We retrospectively recruited patients who underwent invasive coronary angiography within 10 months after Tc-99m sestamibi MPS.

Impact of reconstruction parameters on lesion detection and localization in joint ictal/inter-ictal SPECT reconstruction.

Purpose: Previously, a joint ictal/inter-ictal SPECT reconstruction was proposed to reconstruct a differential image representing the change of brain SPECT image from an inter-ictal to an ictal study. The so-called joint method yielded better performance for epileptic foci localization than the conventional subtraction method. In this study, we evaluated the performance of different reconstruction settings of the joint reconstruction of ictal/inter-ictal SPECT data, which creates a differential image showing the difference between ictal and inter-ictal images, in lesion detection and localization in epilepsy imaging.

Pretherapeutic Comparative Dosimetry of Lu-rhPSMA-7.3 and Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.

Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands allow for labeling with F and radiometals for endoradiotherapy. rhPSMA-7.3 has been designated as a lead compound with promising preclinical data for Lu-rhPSMA-7.

Whole-body uptake classification and prostate cancer staging in Ga-PSMA-11 PET/CT using dual-tracer learning.

Purpose: In PSMA-ligand PET/CT imaging, standardized evaluation frameworks and image-derived parameters are increasingly used to support prostate cancer staging. Clinical applicability remains challenging wherever manual measurements of numerous suspected lesions are required. Deep learning methods are promising for automated image analysis, typically requiring extensive expert-annotated image datasets to reach sufficient accuracy.

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using Lu-FAP-2286: First-in-Humans Results.

Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the first-in-humans results using Lu-FAP-2286 for peptide-targeted radionuclide therapy (PTRT).

Pharmacokinetic Modeling of F-FDOPA PET in the Human Brain for Early Parkinson's Disease.

Objectives: Early detection is essential for the treatment approaches of Parkinson's disease (PD). Clinical criteria alone may be insufficient to distinguish early PD from other conditions. This study aimed to investigate the transfer rate constants of 6-F-fluoro-L-dopa (F-FDOPA) in positron emission tomography (PET) brain images as a sensitive parameter to detect early PD.

Positive Predictive Value and Correct Detection Rate of F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard.

The objective of this retrospective study was to assess the detection rate (DR), positive predictive value (PPV), and correct detection rate (CDR) of F-rhPSMA-7 PET/CT in biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy (RP) using composite validation. F-rhPSMA-7 PET/CT scans of patients with BCR between July 2017 and June 2018 were retrospectively reviewed. All suspicious lesions were recorded.

Usefulness of (99m)Tc-pertechnetate whole body scan with neck and chest SPECT/CT for detection of post-surgical thyroid remnant and metastasis in differentiated thyroid cancer patients.

Objective: The aim of the study was to evaluate the usefulness of (99m)Tc-pertechnetate whole body scan (WBS) with neck and chest SPECT/CT for detection of post-surgical thyroid remnant and metastasis in differentiated thyroid cancer (DTC) patients.

Methods: Fifty-six post total thyroidectomy patients were included. All patients were prospectively imaged with (99m)Tc-pertechnetate WBS with neck and chest SPECT/CT before (131)I ablation.